Company intelligence
Intellia Therapeutics, Inc.
Developing potentially curative genome editing treatments
About Intellia Therapeutics, Inc.
Intellia Therapeutics is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. We are employing our proprietary technologies to create diverse therapeutic approaches spanning a range of diseases to realize Intellia’s full potential and address the needs of patients globally. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/. Intellia Therapeutics, and the Intellia Therapeutics logo are trademarks of Intellia Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and other jurisdictions. © 2026. Intellia Therapeutics, Inc.
Verified activity
Signals from Intellia Therapeutics, Inc.
4 published signals
Legal & Regulatory
Intellia Therapeutics, Inc. received a Biologics License Application (BLA) with Priority Review from the FDA for a potential one-time hereditary angioedema treatment, with a PDUFA target action date of March 10, 2027.
Reported by Intellia Therapeutics, Inc.
Presence & Recognition
Intellia Therapeutics, Inc. will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in NYC on September 14.
Reported by Intellia Therapeutics, Inc.
Presence & Recognition
Intellia Therapeutics, Inc. will present at the upcoming Bradykinin Symposium taking place on Sept. 3-4 in Berlin, Germany.
Reported by Intellia Therapeutics, Inc.
Presence & Recognition
Intellia Therapeutics, Inc. was named a 2026 Fierce 50 honoree in the Breakthrough category.
Reported by Intellia Therapeutics, Inc.